Published in Springer Semin Immunopathol on September 15, 2006
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol (2007) 1.42
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol (2010) 1.33
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS (2013) 0.96
Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther (2012) 0.95
In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine (2009) 0.95
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther (2013) 0.90
Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol (2014) 0.88
Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol (2012) 0.85
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol (2014) 0.83
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infect Dis (2015) 0.83
Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression. J Virol Methods (2009) 0.80
Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors. Sci Rep (2014) 0.78
Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses. Future Virol (2013) 0.78
Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck (2014) 0.78
A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice. PLoS One (2014) 0.77
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine (2016) 0.76
STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma. Cancer Gene Ther (2015) 0.75
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. J Virol (2017) 0.75
The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties. AIDS Res Hum Retroviruses (2014) 0.75
Rapid evolution of RNA genomes. Science (1982) 14.76
RNA virus mutations and fitness for survival. Annu Rev Microbiol (1997) 10.06
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00
Infectious rabies viruses from cloned cDNA. EMBO J (1994) 8.35
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1976) 7.61
Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A (1995) 6.95
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus. J Virol (1975) 5.99
Sequential transcription of the genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1976) 5.88
Genetic characteristics of conditional lethal mutants of vesicular stomatitis virus induced by 5-fluorouracil, 5-azacytidine, and ethyl methane sulfonate. J Virol (1970) 5.43
Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell (1981) 5.38
Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell (1986) 5.19
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol (1999) 3.92
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol (1996) 3.89
COMPARATIVE STUDIES ON THE VIRUSES OF VESICULAR STOMATITIS AND EQUINE ENCEPHALOMYELITIS (1). J Exp Med (1934) 3.85
The ferret: an animal model to study influenza virus. Lab Anim (NY) (2004) 3.75
INFLUENCE OF HOST FACTORS ON NEUROINVASIVENESS OF VESICULAR STOMATITIS VIRUS : I. EFFECT OF AGE ON THE INVASION OF THE BRAIN BY VIRUS INSTILLED IN THE NOSE. J Exp Med (1937) 3.54
Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol (1979) 3.54
Plus and minus strand leader RNAs in negative strand virus-infected cells. Cell (1979) 3.50
[Genetic study of vesicular stomatitis virus: classification of spontaneous thermosensitive mutants into complementation groups]. J Gen Virol (1970) 3.47
N protein of vesicular stomatitis virus selectively encapsidates leader RNA in vitro. Cell (1983) 3.46
Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell (1997) 3.46
Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07
Interaction of VSV leader RNA and nucleocapsid protein may control VSV genome replication. Cell (1981) 3.06
Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol (1999) 3.04
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
The matrix (M) protein of vesicular stomatitis virus regulates transcription. Cell (1978) 2.81
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Determination of molar ratios of vesicular stomatitis virus induced RNA species in BHK21 cells. Biochemistry (1976) 2.69
Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J (1998) 2.64
VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell (2005) 2.55
Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J Virol (1993) 2.54
Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis. Cell (1985) 2.38
Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A (1998) 2.31
Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1995) 2.23
Cell surface expression of fusogenic vesicular stomatitis virus G protein from cloned cDNA. EMBO J (1984) 2.10
Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol (2005) 2.09
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol (1997) 2.07
Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity. J Virol (2004) 2.06
Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology (1999) 2.03
Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol (1992) 2.01
The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol (2000) 1.96
Chandipura: a new Arbovirus isolated in India from patients with febrile illness. Indian J Med Res (1967) 1.89
Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol (1999) 1.89
The budding mechanism of spikeless vesicular stomatitis virus particles. EMBO J (1986) 1.81
Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol (2000) 1.74
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology (2005) 1.74
Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol (1997) 1.72
Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol (2001) 1.70
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Regulation of RNA synthesis by the genomic termini of vesicular stomatitis virus: identification of distinct sequences essential for transcription but not replication. J Virol (1999) 1.58
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol (2001) 1.58
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses (2004) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res (1994) 1.43
Vesicular stomatitis virus (Indiana serotype): transovarial transmission by phlebotomine sandlies. Science (1972) 1.42
Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species. Arch Virol (1995) 1.38
Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci (1998) 1.37
Antigenic relationship among rhabdoviruses infecting terrestrial vertebrates. J Gen Virol (1983) 1.34
Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg (1966) 1.34
The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology (1995) 1.32
Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication. J Virol (1997) 1.31
Cell-free synthesis and assembly of vesicular stomatitis virus nucleocapsids. J Virol (1983) 1.28
Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med (1967) 1.27
Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J Virol (2002) 1.26
Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice. J Neuropathol Exp Neurol (1971) 1.20
The genetics of vesiculoviruses. Arch Virol (1982) 1.16
The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand (1987) 1.13
The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol (2003) 1.12
Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol (2005) 1.09
Neurological manifestations of avian influenza viruses in mammals. Avian Dis (2003) 1.06
Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness. Virology (1998) 1.05
Isolation of Chandipura virus from sandflies in Aurangabad. Indian J Med Res (1970) 1.05
Ecologic studies of vesicular stomatitis virus. II. Results of experimental infection in Panamanian wild animals. Am J Epidemiol (1970) 1.04
Dynamic equilibrium between vesicular stomatitis virus glycoprotein monomers and trimers in the Golgi and at the cell surface. J Virol (1993) 1.03
Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) (2006) 1.02
COCAL VIRUS, A NEW AGENT IN TRINIDAD RELATED TO VESICULAR STOMATITIS VIRUS, TYPE INDIANA. Am J Vet Res (1964) 1.01
Morphological characterisitcs of the pathological process in the central nervous system of monkeys infected with variants of measles virus strain L-16. Acta Virol (1979) 1.01
Isfahan virus, a new vesiculovirus infecting humans, gerbils, and sandflies in Iran. Am J Trop Med Hyg (1977) 1.01
Experimental transmission of Chandipura virus by mosquitoes. Indian J Med Res (1967) 0.97
Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol (2002) 0.97
Carajas and Maraba viruses, two new vesiculoviruses isolated from phlebotomine sand flies in Brazil. Am J Trop Med Hyg (1984) 0.96
The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains. J Infect Dis (1999) 0.93
Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice. J Virol (2003) 0.92
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Ecology: The Convention on Biological Diversity's 2010 target. Science (2005) 5.22
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Southern Ocean iron enrichment experiment: carbon cycling in high- and low-Si waters. Science (2004) 2.43
Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol (2003) 2.39
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet (2006) 1.91
Surveillance for unexplained deaths and critical illnesses due to possibly infectious causes, United States, 1995-1998. Emerg Infect Dis (2002) 1.89
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol (2007) 1.87
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS (2003) 1.76
High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr (2011) 1.74
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing (2005) 1.57
Processing interaural cues in sound segregation by young and middle-aged brains. J Am Acad Audiol (2009) 1.54
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis (2005) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses (2004) 1.45
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
Multidisciplinary approach to the challenge of hemostasis. Anesth Analg (2009) 1.37
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A (2005) 1.36
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS (2004) 1.28
A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res (2012) 1.28
Identification and characterization of a regulatory domain on the carboxyl terminus of the measles virus nucleocapsid protein. J Virol (2002) 1.24
The quality of drinking water from private water supplies in Aberdeenshire, UK. Water Res (2003) 1.15
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS (2002) 1.14
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J Virol (2013) 1.13
An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. J Virol Methods (2006) 1.12
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother (2012) 1.11
Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol (2011) 1.11
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J Infect Dis (2002) 1.10
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials (2002) 1.09
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08
Assessment of stream ecosystem function and sensitivity in the Bighorn National Forest, Wyoming. Environ Manage (2007) 1.07
Harvesting the high-hanging fruit: the structure of the YdeN gene product from Bacillus subtilis at 1.8 angstroms resolution. Acta Crystallogr D Biol Crystallogr (2004) 1.04
Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3). J Med Primatol (2011) 1.03
Establishing a context for river rehabilitation, North Fork Gunnison River, Colorado. Environ Manage (2005) 1.03
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis (2012) 1.02
Role of conformational dynamics in α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor partial agonism. J Biol Chem (2012) 1.01
Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection. J Immunol (2002) 0.99
Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine (2008) 0.98
Structure and function of Bacillus subtilis YphP, a prokaryotic disulfide isomerase with a CXC catalytic motif . Biochemistry (2009) 0.97
Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 0.96
Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr (2002) 0.95
In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine (2009) 0.95
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (2003) 0.93
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother (2003) 0.93
T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis. PLoS One (2011) 0.93
Enhanced genetic rescue of negative-strand RNA viruses: use of an MVA-T7 RNA polymerase vector and DNA replication inhibitors. J Virol Methods (2003) 0.92
An unusual case of peritonitis in an intravenous drug user. Gastroenterology (2011) 0.91
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet (2004) 0.89
Does physical activity in adolescence have site-specific and sex-specific benefits on young adult bone size, content, and estimated strength? J Bone Miner Res (2014) 0.89
Modification of the QuantiFERON-TB Gold (In-Tube) assay for the diagnosis of Mycobacterium bovis infection in African buffaloes (Syncerus caffer). Vet Immunol Immunopathol (2011) 0.88
Influence of vascular porosity on fluid flow and nutrient transport in loaded cortical bone. J Biomech (2008) 0.88
Role of V protein RNA binding in inhibition of measles virus minigenome replication. Virology (2006) 0.88
A national framework for disaster health education in Australia. Prehosp Disaster Med (2010) 0.87
Strengthening international cooperation for health and biodiversity. Ecohealth (2012) 0.87
Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology (2006) 0.87
Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates. Virus Res (2005) 0.85
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr (2013) 0.85
Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses. Vaccine (2008) 0.84
Inhibition of measles virus minireplicon-encoded reporter gene expression by V protein. Virology (2006) 0.84
Joint statement on mechanical circulatory support in children: a consensus review from the Pediatric Cardiac Intensive Care Society and Extracorporeal Life Support Organization. Pediatr Crit Care Med (2013) 0.84
Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models. J Virol (2005) 0.84
Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine (2005) 0.84
Improved compressed sensing-based algorithm for sparse-view CT image reconstruction. Comput Math Methods Med (2013) 0.84
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother (2015) 0.83